JP2013508388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508388A5 JP2013508388A5 JP2012535338A JP2012535338A JP2013508388A5 JP 2013508388 A5 JP2013508388 A5 JP 2013508388A5 JP 2012535338 A JP2012535338 A JP 2012535338A JP 2012535338 A JP2012535338 A JP 2012535338A JP 2013508388 A5 JP2013508388 A5 JP 2013508388A5
- Authority
- JP
- Japan
- Prior art keywords
- botulinum toxin
- column
- unconjugated
- type
- gradient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108030001720 Bontoxilysin Proteins 0.000 claims 25
- 229940053031 botulinum toxin Drugs 0.000 claims 25
- 238000000034 method Methods 0.000 claims 25
- 238000011068 loading method Methods 0.000 claims 6
- 229920002684 Sepharose Polymers 0.000 claims 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 238000005349 anion exchange Methods 0.000 claims 4
- 125000000129 anionic group Chemical group 0.000 claims 4
- 230000001174 ascending effect Effects 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 4
- 125000002091 cationic group Chemical group 0.000 claims 4
- 238000005341 cation exchange Methods 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 239000002244 precipitate Substances 0.000 claims 3
- 101710163270 Nuclease Proteins 0.000 claims 2
- 238000009295 crossflow filtration Methods 0.000 claims 2
- 239000003480 eluent Substances 0.000 claims 2
- 238000000855 fermentation Methods 0.000 claims 2
- 230000004151 fermentation Effects 0.000 claims 2
- 239000001103 potassium chloride Substances 0.000 claims 2
- 235000011164 potassium chloride Nutrition 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 1
- 239000007995 HEPES buffer Substances 0.000 claims 1
- 239000007987 MES buffer Substances 0.000 claims 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000003916 acid precipitation Methods 0.000 claims 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 claims 1
- 229940094657 botulinum toxin type a Drugs 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 238000012136 culture method Methods 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims 1
- CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- IRHWMYKYLWNHTL-UHFFFAOYSA-M sodium 2-(N-morpholino)ethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCN1CCOCC1 IRHWMYKYLWNHTL-UHFFFAOYSA-M 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25381009P | 2009-10-21 | 2009-10-21 | |
| US61/253,810 | 2009-10-21 | ||
| PCT/US2010/053389 WO2011050072A1 (en) | 2009-10-21 | 2010-10-20 | Methods and systems for purifying non-complexed botulinum neurotoxin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013508388A JP2013508388A (ja) | 2013-03-07 |
| JP2013508388A5 true JP2013508388A5 (enExample) | 2013-09-26 |
| JP5951490B2 JP5951490B2 (ja) | 2016-07-13 |
Family
ID=43879799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535338A Active JP5951490B2 (ja) | 2009-10-21 | 2010-10-20 | 非複合ボツリヌス神経毒素を精製するための方法およびシステム |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US20120196349A1 (enExample) |
| EP (1) | EP2490986B2 (enExample) |
| JP (1) | JP5951490B2 (enExample) |
| KR (1) | KR101819129B1 (enExample) |
| CN (2) | CN104961812B (enExample) |
| AU (1) | AU2010310749B2 (enExample) |
| BR (1) | BR112012009227A2 (enExample) |
| CA (1) | CA2773396C (enExample) |
| CO (1) | CO6551670A2 (enExample) |
| CY (1) | CY1120908T1 (enExample) |
| DK (1) | DK2490986T4 (enExample) |
| ES (1) | ES2688065T5 (enExample) |
| HR (1) | HRP20181869T1 (enExample) |
| HU (1) | HUE041599T2 (enExample) |
| IL (2) | IL218532A (enExample) |
| LT (1) | LT2490986T (enExample) |
| MX (3) | MX2012004703A (enExample) |
| PH (1) | PH12012500549A1 (enExample) |
| PL (1) | PL2490986T3 (enExample) |
| PT (1) | PT2490986T (enExample) |
| RS (1) | RS58006B1 (enExample) |
| SI (1) | SI2490986T1 (enExample) |
| SM (1) | SMT201800487T1 (enExample) |
| WO (1) | WO2011050072A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2379104T (lt) | 2008-12-31 | 2018-04-10 | Revance Therapeutics, Inc. | Injekcinės botulino toksino vaisto formos |
| CN102869373B (zh) * | 2009-06-25 | 2017-05-10 | 雷文斯治疗公司 | 不含白蛋白的肉毒杆菌毒素制剂 |
| US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| US20120196349A1 (en) * | 2009-10-21 | 2012-08-02 | Revance Therapeutics, Inc. | Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin |
| KR101134146B1 (ko) * | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| KR102272580B1 (ko) | 2013-07-30 | 2021-07-05 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도 |
| KR101339349B1 (ko) * | 2013-08-02 | 2013-12-09 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| KR102463881B1 (ko) | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
| EP3675900A4 (en) | 2017-08-28 | 2021-05-05 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
| CA3124535A1 (en) | 2018-12-21 | 2020-06-25 | The Research Foundation For Microbial Diseases Of Osaka University | Botulinum toxin producing method |
| KR102485146B1 (ko) | 2019-04-15 | 2023-01-06 | (주)제테마 | 보툴리눔 독소의 제조방법 |
| KR102447441B1 (ko) * | 2019-04-15 | 2022-09-27 | (주)제테마 | 보툴리눔 독소의 정제방법 |
| US10851363B1 (en) * | 2019-05-22 | 2020-12-01 | Boke Zhang | Multilayer nano-cell containing biomolecules |
| KR20230146049A (ko) * | 2021-02-26 | 2023-10-18 | 충칭 클라루비스 파마슈티컬 컴퍼니 리미티드 | 폴리펩티드를 제조하기 위한 세포 용해 버퍼 분리 장비, 시스템 및 이의 용도 |
| CN114958887B (zh) * | 2021-02-26 | 2024-10-25 | 重庆誉颜制药有限公司 | 一种经修饰的毒素多肽的制备方法 |
| KR102724650B1 (ko) * | 2021-07-05 | 2024-11-01 | 주식회사 파마리서치바이오 | 클로스트리디움 보툴리눔 독소 복합체 단백질의 정제방법 |
| KR102724651B1 (ko) * | 2021-07-08 | 2024-11-01 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
| KR102512757B1 (ko) * | 2021-07-22 | 2023-03-22 | (주)이니바이오 | 정제 수율이 향상된 보툴리눔 독소 복합체 정제방법 |
| US20250018016A1 (en) * | 2021-11-15 | 2025-01-16 | Medytox Inc. | Botulinum neurotoxin composition |
| TWI890364B (zh) * | 2023-03-16 | 2025-07-11 | 南韓商大熊股份有限公司 | 使用多模式層析法純化肉毒毒素的改進方法 |
| CN122514358A (zh) | 2023-09-19 | 2026-08-04 | 雷文斯治疗公司 | 需要快速起效美容效果和更平滑皮肤外观的患者中的使用肉毒毒素的治疗 |
| DE102025101336A1 (de) | 2024-01-19 | 2025-07-24 | Abbvie Inc. | Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse |
| KR102945108B1 (ko) * | 2024-06-19 | 2026-04-02 | (주)제테마 | 클로스트리디움 보툴리눔 독소의 정제방법 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US796419A (en) | 1904-07-18 | 1905-08-08 | Carl Halbig | Doll-head. |
| SE303567B (enExample) * | 1959-02-17 | 1968-09-02 | Behringwerke Ag | |
| US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| WO1999037326A1 (en) * | 1998-01-26 | 1999-07-29 | University Of Massachusetts | Biologically active hemagglutinin from type a clostridium botulinum and methods of use |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| DE19925739A1 (de) † | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| GB9921592D0 (en) * | 1999-09-13 | 1999-11-17 | Microbiological Res Authority | Preparation of highly pure toxin fragments |
| DK1301213T3 (en) * | 2000-07-21 | 2017-03-27 | Revance Therapeutics Inc | MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| GB2386246B (en) | 2001-11-01 | 2005-06-29 | Marconi Applied Techn Ltd | Electron beam tube apparatus |
| US7118901B2 (en) * | 2002-12-18 | 2006-10-10 | Roche Diagnostics Operations, Inc. | Recombinant bovine pancreatic desoxyribonuclease I with high specific activity |
| KR100498964B1 (ko) | 2003-03-05 | 2005-07-01 | 삼성전자주식회사 | 이동단말에서의 전자파 흡수율 제어 방법 및 장치 |
| AU2003271835A1 (en) * | 2003-06-06 | 2005-01-04 | Avecia Limited | Process for the separation of proteins |
| US7452697B2 (en) | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
| JP2007535911A (ja) * | 2003-12-30 | 2007-12-13 | バハラ バイオテック インターナショナル リミテッド | 組換えタンパク質の製造及び精製方法 |
| KR20050074806A (ko) * | 2004-01-14 | 2005-07-19 | 팜텍(주) | 결정형 보툴리늄 독소의 제조방법 |
| HUE025656T2 (en) * | 2004-03-03 | 2016-04-28 | Revance Therapeutics Inc | Topical application and transdermal delivery of botulinum toxins |
| BRPI0508440A (pt) * | 2004-03-03 | 2007-07-24 | Revance Therapeutics Inc | composições e métodos para diagnóstico tópico e transporte terapêutico |
| CN1930186A (zh) * | 2005-03-03 | 2007-03-14 | 阿勒根公司 | 为获得梭菌毒素的梭菌细菌培养基及方法 |
| HRP20090382T1 (hr) * | 2005-06-17 | 2009-09-30 | Merz Pharma Gmbh & Co.Kgaa | Uređaj i postupak za proizvodnju biološko aktivnih spojeva fermentacijom |
| US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| EP2085093B1 (en) * | 2006-10-27 | 2015-02-25 | The Chemo-Sero-Therapeutic Research Institute | Preparation containing highly purified botulinum toxin type a derived from infant botulism pathogen |
| CN100588706C (zh) * | 2007-04-06 | 2010-02-10 | 常州千红生化制药股份有限公司 | 纯化弹性蛋白酶的方法 |
| AU2008256418A1 (en) * | 2007-06-01 | 2008-12-04 | Merz Pharma Gmbh & Co. Kgaa | Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form |
| JP5344558B2 (ja) * | 2008-10-31 | 2013-11-20 | 国立大学法人 東京医科歯科大学 | カチオン性ナノゲルを用いる粘膜ワクチン |
| LT2379104T (lt) * | 2008-12-31 | 2018-04-10 | Revance Therapeutics, Inc. | Injekcinės botulino toksino vaisto formos |
| US8440204B2 (en) * | 2009-04-30 | 2013-05-14 | Wisconsin Alumni Research Foundation | Subtype of Closteridium botulinum neurotoxin type A and uses thereof |
| CN102869373B (zh) * | 2009-06-25 | 2017-05-10 | 雷文斯治疗公司 | 不含白蛋白的肉毒杆菌毒素制剂 |
| US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| JP2011074025A (ja) * | 2009-09-30 | 2011-04-14 | Chemo-Sero-Therapeutic Research Inst | ボツリヌス毒素の精製方法 |
| US20120196349A1 (en) * | 2009-10-21 | 2012-08-02 | Revance Therapeutics, Inc. | Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin |
| US8440104B2 (en) * | 2009-10-21 | 2013-05-14 | General Electric Company | Kimzeyite garnet phosphors |
| US20150204884A1 (en) * | 2012-06-01 | 2015-07-23 | Momenta Pharmaceuticals, Inc. | Methods of evaluating and making biologics |
| WO2014066916A2 (en) * | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| CN109069608A (zh) * | 2015-10-29 | 2018-12-21 | 雷文斯治疗公司 | 具有长的治疗或美容效应持续时间的可注射肉毒杆菌毒素制剂以及其使用方法 |
| KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| AU2018270092C1 (en) * | 2017-05-18 | 2026-01-08 | Revance Therapeutics, Inc. | Methods of treatment for cervical dystonia |
-
2010
- 2010-10-20 US US13/394,506 patent/US20120196349A1/en not_active Abandoned
- 2010-10-20 CA CA2773396A patent/CA2773396C/en active Active
- 2010-10-20 ES ES10825598T patent/ES2688065T5/es active Active
- 2010-10-20 BR BR112012009227A patent/BR112012009227A2/pt not_active IP Right Cessation
- 2010-10-20 EP EP10825598.5A patent/EP2490986B2/en active Active
- 2010-10-20 HU HUE10825598A patent/HUE041599T2/hu unknown
- 2010-10-20 LT LTEP10825598.5T patent/LT2490986T/lt unknown
- 2010-10-20 PT PT10825598T patent/PT2490986T/pt unknown
- 2010-10-20 HR HRP20181869TT patent/HRP20181869T1/hr unknown
- 2010-10-20 PL PL10825598T patent/PL2490986T3/pl unknown
- 2010-10-20 CN CN201510173705.8A patent/CN104961812B/zh active Active
- 2010-10-20 US US12/908,647 patent/US20110092682A1/en not_active Abandoned
- 2010-10-20 RS RS20181330A patent/RS58006B1/sr unknown
- 2010-10-20 SI SI201031746T patent/SI2490986T1/sl unknown
- 2010-10-20 AU AU2010310749A patent/AU2010310749B2/en active Active
- 2010-10-20 DK DK10825598.5T patent/DK2490986T4/da active
- 2010-10-20 MX MX2012004703A patent/MX2012004703A/es active IP Right Grant
- 2010-10-20 MX MX2015011592A patent/MX365496B/es unknown
- 2010-10-20 KR KR1020127012224A patent/KR101819129B1/ko active Active
- 2010-10-20 SM SM20180487T patent/SMT201800487T1/it unknown
- 2010-10-20 PH PH1/2012/500549A patent/PH12012500549A1/en unknown
- 2010-10-20 WO PCT/US2010/053389 patent/WO2011050072A1/en not_active Ceased
- 2010-10-20 CN CN201080045567.0A patent/CN102666396B/zh active Active
- 2010-10-20 JP JP2012535338A patent/JP5951490B2/ja active Active
-
2012
- 2012-03-07 IL IL218532A patent/IL218532A/en active IP Right Grant
- 2012-04-20 MX MX2019006519A patent/MX2019006519A/es unknown
- 2012-04-30 CO CO12070154A patent/CO6551670A2/es not_active Application Discontinuation
-
2015
- 2015-07-10 US US14/796,235 patent/US9469849B2/en active Active
-
2016
- 2016-10-17 US US15/295,134 patent/US20170029795A1/en not_active Abandoned
- 2016-10-25 IL IL248486A patent/IL248486A0/en unknown
-
2018
- 2018-09-25 CY CY181100988T patent/CY1120908T1/el unknown
-
2019
- 2019-12-02 US US16/700,728 patent/US11466262B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX340718B (es) | Proceso y sistema para obtener neurotoxina botulinica. | |
| JP6593721B2 (ja) | 高純度の組換えヒト血清アルブミンを単離、精製するクロマトグラフ法 | |
| JP5948343B2 (ja) | トランスジェニックイネの子実からヒト血清アルブミンを精製する方法 | |
| AR121861A2 (es) | MÉTODO PARA PREPARAR UNA COMPOSICIÓN DE IgG ENRIQUECIDA A PARTIR DE PLASMA | |
| MX2015005178A (es) | Purificacion de polipeptidos usando ultrafiltracion de flujo tangencial de etapa doble. | |
| CN103687600B (zh) | 一种制备多糖的方法 | |
| WO2018228246A1 (zh) | 一种酶法制备谷胱甘肽的方法 | |
| JP2012532932A5 (enExample) | ||
| GB2443505B (en) | Nucleic acid purification method | |
| JP2016519137A5 (enExample) | ||
| AR091647A1 (es) | Purificacion de iduronato-2-sulfatasa | |
| DK1268399T3 (da) | Fremgangsmåde til separering af en basisk aminosyre fra fermenteringsvæske | |
| CN103497248B (zh) | 一种从细胞培养上清中分离纯化抗体的方法 | |
| US10377812B2 (en) | Method for efficient purification of human serum albumin | |
| MX2025006822A (es) | Lavado con arginina en la purificacion de proteinas | |
| WO2015088625A3 (en) | Compounds and methods of promoting myelination | |
| CN105273041A (zh) | 一种蛋白质亲和层析洗脱方法 | |
| CN103013951B (zh) | 一种提取纯化小麦胚芽脂肪酶的方法 | |
| CN103224920A (zh) | 一种枯草芽孢杆菌耐高温β-淀粉酶分离纯化的方法 | |
| CN110759959A (zh) | 一种从发酵液中分离提取维生素b12的方法 | |
| CN104004091B (zh) | 一种人免疫球蛋白的制备工艺 | |
| CN104478949B (zh) | 一种海藻糖和麦芽糖的色谱分离方法 | |
| MX2024004764A (es) | Procedimiento para purificar una proteína de fusión que tiene un dominio fc de igg. | |
| CN105112402A (zh) | 一种植物线粒体dna的快速提取方法 | |
| CN101831417A (zh) | 一种l-门冬酰胺酶的制备方法 |